Skip to Content for FAQs Menu for FAQs About Us Menu Research Menu Development Menu Medicines Menu Investors Menu Media Menu Careers Menu
Banner Image

FAQs

Q: What exchange is Genentech stock listed on--what is your stock symbol?
A: Genentech is listed on the New York Stock Exchange under the symbol DNA.
Back to Top Back to Top
Q:
 What is your stock's CUSIP#?
A:
 The CUSIP# for the Genentech Common Stock is 368710 40 6.
Back to Top Back to Top
Q:
 Where is Genentech incorporated?
A:
 Genentech became a Delaware corporation on January 28, 1987.
Back to Top Back to Top
Q:
 Where is Genentech's headquarters?
A:
 South San Francisco, California Our mailing address is: 1 DNA Way, South San Francisco, CA 94080-4990
Back to Top Back to Top
Q:
 Can I purchase shares directly from the company?
A:
 No, Genentech does not have a direct stock purchase plan. Shares may be purchased through a broker of your choice.
Back to Top Back to Top
Q:
 Do you have a DRIP (Dividend Reinvestment Plan)?
A:
 No, Genentech does not pay a dividend and therefore does not have such a program.
Back to Top Back to Top
Q:
 Do you anticipate paying a dividend?
A:
 The payment of a dividend is not foreseen in the near future.
Back to Top Back to Top
Q:
 Who is Genentech's Transfer Agent?
A:
 Computershare Trust Company, N.A.
c/o Computershare Investor Centre
P.O. Box 43078
Providence, RI 02940-3078
Attn: Shareholder Inquiries

Telephone: (800) 733-5001
www.computershare.com
Back to Top Back to Top
Q:
 I've lost my stock certificates, how can I replace them?
A:
 Contact our Transfer Agent, Computershare.

Computershare Trust Company, N.A.
c/o Computershare Investor Centre
P.O. Box 43078
Providence, RI 02940-3078
Attn: Shareholder Inquiries

Telephone: (800) 733-5001
www.computershare.com
Back to Top Back to Top
Q:
 Who should I notify in the event of a change of address?
A:
 Communication regarding change of address should be directed to our transfer agent, Computershare. Computershare Trust Company, N.A.
c/o Computershare Investor Centre
P.O. Box 43078
Providence, RI 02940-3078
Attn: Shareholder Inquiries

Telephone: (800) 733-5001
www.computershare.com
Back to Top Back to Top
Q:
 Who can help me with transferring my certificates into a trust or another name?
A:
 Transfer requirement inquiries should be directed to the transfer agent, Computershare. Computershare Trust Company, N.A.
c/o Computershare Investor Centre
P.O. Box 43078
Providence, RI 02940-3078
Attn: Shareholder Inquiries

Telephone: (800) 733-5001
www.computershare.com
Back to Top Back to Top
Q:
 When is your annual meeting of stockholders?
A:
 The 2008 Annual Meeting of Stockholders will be held in April, 2008. Date, time and location to be announced.
Back to Top Back to Top
Q:
 Have you had any stock splits?
A:
 Yes, six. 1. 3-for-2. Payable date: 3/30/83; record date: 3/2/83; traded at split price on 3/31/83
2. 2-for-1. Payable date: 2/28/86; record date: 2/1/86; traded at split price on 3/1/86
3. 2-for-1. Payable date: 2/27/87; record date: 1/28/87; traded at split price on 3/2/87
4. 2-for-1. Payable date: 11/2/99; record date: 10/29/99; traded at split price on 11/3/99
5. 2-for-1. Payable date: 10/24/00; record date: 10/17/00; traded at split price on 10/25/00
6. 2-for-1. Payable date: 5/12/04; record date: 4/28/04; traded at split price on 5/13/04
Back to Top Back to Top
Q:
 How many shares are outstanding/how many shares does Roche own?
A:
 As of December 31, 2006, there were approximately 1,052.9 million shares outstanding. Roche held approximately 587.2 million shares or 55.8%.
Back to Top Back to Top
Q:
 How many employees does Genentech have?
A:
 As of December 31, 2006, Genentech had approximately 10,460 employees.
Back to Top Back to Top
Q:
 What dates were Genentech's products approved?
A:
Product
 Indication
 U.S. FDA Approval
*Protropin®, growth hormone
 Growth hormone deficiency in children
 10/17/1985
 
Nutropin®, growth hormone
 Growth failure associated with chronic renal insufficiency
 11/17/1993
 
 Growth hormone deficiency in children
 03/08/1994
 
 Short stature associated with Turner Syndrome
 12/30/1996
 
 Growth hormone deficiency in adults
 12/15/1997
 
 Long-term treatment of children with idiopathic short stature defined by height SDS < -2.25 (also called non-growth hormone-deficient short stature)
 06/28/2005
 
Nutropin AQ®, liquid formulation growth hormone
 Growth failure associated with chronic renal insufficiency
 12/29/1995
 
 Growth hormone deficiency in children
 12/29/1995
 
 Short stature associated with Turner Syndrome
 03/24/1997
 
 Growth hormone deficiency in adults
 12/17/1997
 
 Long-term treatment of children with idiopathic short stature defined by height SDS < -2.25 (also called non-growth hormone-deficient short stature)
 06/28/2005
 
Activase®, tissue plasminogen activator
 Acute Myocardial Infarction (Heart Attack)
 11/13/1987
 
 Pulmonary Embolism
 06/05/1990
 
 Acute Ischemic Stroke (within 3 hours of symptom onset)
 06/18/1996
 
Pulmozyme®, inhalation solution
 Management of Cystic Fibrosis (CF)
 12/29/1993
 
 Treatment of CF Patients with Advanced Disease
 11/26/1996
 
 Treatment of CF patients under the age of 5
 02/24/1998
 
Rituxan®, antibody
 Relapsed or refractory low-grade or follicular, CD20 positive B-cell non-Hodgkin's lymphoma
 11/26/1997
 
 For the first-line treatment of diffuse large B-cell, CD20-positive, non-Hodgkin's lymphoma (DLBCL- a type of NHL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens
 02/10/2006
 
 In combination with methotrexate (MTX) for the treatment of adult patients with moderately- to severely-active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
 2/28/2006
 
 For first-line treatment in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy in patients with follicular, CD-20 positive, B-cell non-Hodgkins lymphoma.
 9/29/2006
 
 For treatment of low-grade, CD-20 positive, B-cell non-Hodgkins lymphoma in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy.
 9/29/2006
 
 In combination with methotrexate (MTX) to slow the progression of structural damage in adult patients with moderately-to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
 01/25/2008
 
Herceptin®, antibody
 In combination with paclitaxel for treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein; and as a single agent for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease.
 09/25/1998
  As part of a treatment regimen containing doxorubicin, cyclophosphamide and paclitaxel, for the adjuvant treatment of patients with HER2-positive, node-positive breast cancer.
 11/16/2006
  Adjuvant treatment of HER2-overexpressing node-negative (ER/PR-negative or with one high-risk feature) or node-positive breast cancer, following multi-modality anthracycline-based therapy.
 01/18/2008
 
*Nutropin Depot®, encapsulated sustained-release growth hormone
 Growth hormone deficiency in children
 12/22/1999
 
TNKase®, single-bolus thrombolytic agent
 Acute Myocardial Infarction (Heart Attack)
 06/02/2000
 
CathfloTM Activase® (Alteplase), a tissue plasminogen activator (t-PA)
 Restoration of function to central venous access devices (CVADs)
 09/04/2001
 
Xolair® (Omalizumab) For Subcutaneous Use
 Treatment of moderate-to-severe persistent asthma in adults and adolescents (12 years of age or above)
 06/20/2003
 
Raptiva® (efalizumab)
 Treatment of chronic moderate-to-severe plaque psoriasis in adults 18 years or older who are candidates for systemic therapy or phototherapy
 10/27/2003
 
Avastin® (bevacizumab)
 For use in combination with intravenous 5-Fluorouracil-based chemotherapy as a treatment for patients with first-line metastatic cancer of the colon or rectum
 2/26/2004
 
 For use in combination with intravenous 5-Fluorouracil-based chemotherapy as a treatment for patients with second-line metastatic cancer of the colon or rectum
 6/20/2006
 
 In combination with carboplatin and paclitaxel, for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer
 10/11/2006
 
Tarceva® (erlotinib)
 For use as an oral tablet for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
 11/18/2004

For use in combination with gemcitabine chemotherapy for the first-line treatment of patients with locally advanced, inoperable or metastatic pancreatic cancer
 11/02/2005
 
Lucentis® (ranibizumab injection)
 For the treatment of neovascular (wet) age-related macular degeneration (AMD)
 6/30/2006
 
 *Protropin and Nutropin Depot were discontinued in 2004.
Back to Top Back to Top
Q:
 What has happened to 100 shares of Genentech stock purchased at Genentech's 1980 IPO with the amount of the investment maintained through May 2004?
A:

Based on corporate transactions between Roche and Genentech that occurred between 1990 to 1999 (as described in Stock Events Timeline), it is not possible for an investor to hold today shares of Genentech purchased in 1980. However, assuming that any cash payouts to an investor from such corporate transactions were reinvested in Genentech stock at the prices indicated below, the initial investment in 100 shares would have grown to 5,040 shares.*

Date
 Event
October 14, 1980
IPO1
 100 shares of Genentech Common Stock purchased @ $35.00 per share1
March 30, 1983
3-for-2 split
 100 shares becomes 150 shares @ $23.33 per share
February 28, 1986
2-for-1 split
150 shares becomes 300 shares @ $11.67 per share
February 27, 1987
2-for-1 split
300 shares becomes 600 shares @ $5.83 per share
September 7, 1990
Roche merger
 600 shares of Genentech Common Stock are exchanged for 300 shares of Genentech Redeemable Common Stock and $10,800.00 (600 shares x 1/2 share = 300 shares + 600 shares x $18 = $10,800)
September 10, 1990
Reinvestment2
Reinvest the $10,800.00 received in 9/7/90 transaction (@ $22.75) = 474 shares, resulting in a total ownership of 774 shares (300 shares + 474 shares)2
October 25, 1995
Exchange
 774 shares of Genentech Redeemable Common Stock are exchanged for 774 shares of Genentech Callable Putable Common Stock
June 30, 1999
Roche acquisition
 Receive $63,855.00 in exchange for 774 shares (774 shares x $82.50)
July 19, 1999
Reinvestment in DNA offering3
Reinvest $48,500.00 of the $63,855.00 received in the 6/30/99 transaction into DNA shares (500 shares @$97.00)3
July 20, 1999
Reinvestment4
 Reinvest $15,340.00 of the $15,355.00 received in the 6/30/99 transaction in open market purchase of DNA (130 shares @ $118.00) Now own 630 shares (average cost per share of $101.33)4
November 2, 1999
2-for-1 split
630 shares becomes 1,260 shares (average cost per share of $50.67)
October 24, 2000
2-for-1 split
1,260 shares becomes 2,520 shares (average cost per share of $25.33)
May 12, 2004
2-for-1 split
2,520 shares becomes 5,040 shares (average cost per share of $12.67)

*Please note that the following assumptions have been made in order to arrive at this calculation. It is provided as an example only, and in no way suggests that each stockholder's experience has been similar to this example. Please consult with your financial advisor to determine which events have impacted your ownership in Genentech stock to calculate your individual ownership position and cost basis.

Calculation Assumptions:  
1October 14, 1980
 The offering price in Genentech's initial public offering was $35.00. The high/low trading range on this day was $38.00-$88.00.
2September 10, 1990
 Genentech's redeemable common stock begins trading. The opening price was $22.75. The high/low trading range on this day was $22.625-$23.875 (closing at $23.875).
3July 19, 1999
 Roche's offering of Genentech shares to the public. The offering price was $97.00. A maximum of 500 shares was allowed for purchase by former stockholders and Genentech employees.
4July 20, 1999
 Genentech's Common Stock begins trading on NYSE under the symbol DNA. The opening price was $118.00. The high/low trading range was $116.50-$132.00 (closing at $127.00).
Back to Top Back to Top